Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

Krop, IE; Kim, SB; Martin, AG; LoRusso, PM; Ferrero, JM; Badovinac-Crnjevic, T; Hoersch, S; Smitt, M; Wildiers, H

Krop, IE (reprint author), Dana Farber Canc Inst, Breast Oncol, Boston, MA 02215 USA.

LANCET ONCOLOGY, 2017; 18 (6): 743

Abstract

Background In the randomised, parallel assignment, open-label, phase 3 TH3RESA study, progression-free survival was significantly longer with trastuzu......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索